Neutrophil interactions with intestinal epithelial cells
中性粒细胞与肠上皮细胞的相互作用
基本信息
- 批准号:7847792
- 负责人:
- 金额:$ 31万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-09-30 至 2011-02-28
- 项目状态:已结题
- 来源:
- 关键词:AcuteAdoptive TransferAnimalsB-LymphocytesBiological AssayBone MarrowBone Marrow CellsCellsChimera organismColitisColonComplementDefectDevelopmentDiseaseDisease modelEpithelialEpithelial CellsEpitheliumEtiologyExcisionFaceFamily memberFunctional disorderFundingGenerationsHomeostasisHumanHyperplasiaImmuneImmune responseImmunoglobulin AIn VitroInflammatory Bowel DiseasesInflammatory disease of the intestineIntestinesKnock-outKnockout MiceLeukocytesMediatingModelingMucositisMucous MembraneMusPeritonitisPermeabilityPhagocytosisPhenotypePlayProtein FamilyProteinsRecoveryRegulationResearchRestRoleSecondary toSeriesSmall Interfering RNASystemT-LymphocyteTight JunctionsUnited States National Institutes of HealthZymosancell typeimmune functionin vivojunctional adhesion moleculeknockout animalmonolayermouse developmentneutrophilpublic health relevanceresearch studyresponsesalmonella colitistherapeutic target
项目摘要
DESCRIPTION (provided by applicant): Response to Notice Number (NOT-OD-09-058), Notice Title: NIH Announces the Availability of Recovery Funds for Competitive Revision Applications. The etiology of human inflammatory bowel disease (IBD) includes both aberrant leukocyte responses and epithelial barrier dysfunction. Junctional Adhesion Molecule (JAM) family of proteins have been shown to regulate both epithelial tight junction function and leukocyte transmigration. Our results suggest that JAM proteins play an important role in the pathophysiology of intestinal mucosal inflammation such as observed in IBD. JAM-A is the best characterized family member to date, but in-vivo studies of JAM-A function have been limited and the results often contradictory. One difficulty has been determining the role of JAM-A on multiple cell types potentially contributing to observed phenotypes. Focused experiments employing bone marrow chimeras and relevant disease models alongside complementary in vitro systems will provide the means to dissect the important contributions of epithelial and leukocyte JAM-A to mucosal permeability and intestinal inflammation. Our preliminary results suggest an important role for JAM-A in regulation of PMN recruitment in the intestine and detail findings consistent with compensatory B-cell hyperplasia that may protect these animals from developing spontaneous colitis in face of a large increase in colonic permeability. These observations suggest that JAM-A plays a central role in intestinal homeostasis by direct regulation of leukocyte function and by indirect means through regulation of permeability of the colonic epithelium. Further research extending these findings is clearly warranted and may significantly enhance our understanding of the relationship between JAMs and mucosal homeostasis and, more broadly, basic regulation of mucosal immune function.
PUBLIC HEALTH RELEVANCE: Human inflammatory bowel disease (IBD) is characterized by both aberrant leukocyte responses and intestinal barrier dysfunction. Research focused on the contributions of junctional adhesion molecule-A (JAM-A) to mucosal permeability and intestinal inflammation should, therefore, be highly relevant in understanding pathophysiology of IBD and in the development of therapeutic targets to ameliorate intestinal inflammation.
描述(由申请人提供):对通知号(NOT-OD-09-058)的回应,通知标题:NIH宣布可获得竞争性修订申请的恢复资金。人类炎症性肠病(IBD)的病因包括异常的白细胞反应和上皮屏障功能障碍。连接粘附分子(JAM)蛋白家族已被证明调节上皮紧密连接功能和白细胞迁移。我们的研究结果表明JAM蛋白在肠黏膜炎症的病理生理中发挥重要作用,如在IBD中观察到的。JAM-A是迄今为止最具特征的家族成员,但对JAM-A功能的体内研究有限,结果往往相互矛盾。一个困难是确定JAM-A在多种细胞类型上的作用,可能会导致观察到的表型。利用骨髓嵌合体和相关疾病模型以及互补的体外系统进行的重点实验将为解剖上皮细胞和白细胞JAM-A对粘膜通透性和肠道炎症的重要贡献提供手段。我们的初步结果表明JAM-A在调节肠道PMN募集中起重要作用,详细的发现与代偿性b细胞增生一致,这可能保护这些动物在面对结肠通透性大量增加时免于发生自发性结肠炎。这些观察结果表明,JAM-A通过直接调节白细胞功能和间接调节结肠上皮通透性,在肠道稳态中发挥核心作用。对这些发现进行进一步的研究显然是有必要的,并且可能会显著增强我们对JAMs与粘膜稳态之间关系的理解,更广泛地说,是对粘膜免疫功能基本调节的理解。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CHARLES A PARKOS其他文献
CHARLES A PARKOS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CHARLES A PARKOS', 18)}}的其他基金
Structure function studies in intestinal epithelial JAM
肠上皮JAM的结构功能研究
- 批准号:
7898173 - 财政年份:2009
- 资助金额:
$ 31万 - 项目类别:
Role of signal regulatory protein in neutrophil function
信号调节蛋白在中性粒细胞功能中的作用
- 批准号:
7086257 - 财政年份:2003
- 资助金额:
$ 31万 - 项目类别:
Emory Epithelial Pathobiology Research Development Center
埃默里大学上皮病理学研究发展中心
- 批准号:
8288323 - 财政年份:2003
- 资助金额:
$ 31万 - 项目类别:
Role of signal regulatory protein in neutrophil function
信号调节蛋白在中性粒细胞功能中的作用
- 批准号:
6936644 - 财政年份:2003
- 资助金额:
$ 31万 - 项目类别:
Emory Epithelial Pathobiology Research Development Center
埃默里大学上皮病理学研究发展中心
- 批准号:
8080876 - 财政年份:2003
- 资助金额:
$ 31万 - 项目类别:
Role of signal regulatory protein in neutrophil function
信号调节蛋白在中性粒细胞功能中的作用
- 批准号:
6684457 - 财政年份:2003
- 资助金额:
$ 31万 - 项目类别:
Role of signal regulatory protein in neutrophil function
信号调节蛋白在中性粒细胞功能中的作用
- 批准号:
6765880 - 财政年份:2003
- 资助金额:
$ 31万 - 项目类别:
Structure function studies in intestinal epithelial JAM
肠上皮JAM的结构功能研究
- 批准号:
8451327 - 财政年份:2002
- 资助金额:
$ 31万 - 项目类别:
Structure function studies in intestinal epithelial JAM
肠上皮JAM的结构功能研究
- 批准号:
8662243 - 财政年份:2002
- 资助金额:
$ 31万 - 项目类别:
Intestinal Inflammation: Signaling proteins and the rate of PMN transmigration
肠道炎症:信号蛋白和 PMN 迁移率
- 批准号:
10428645 - 财政年份:2002
- 资助金额:
$ 31万 - 项目类别:
相似海外基金
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 31万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10576370 - 财政年份:2022
- 资助金额:
$ 31万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10387023 - 财政年份:2022
- 资助金额:
$ 31万 - 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10248409 - 财政年份:2019
- 资助金额:
$ 31万 - 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
- 批准号:
nhmrc : GNT1163111 - 财政年份:2019
- 资助金额:
$ 31万 - 项目类别:
Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10462684 - 财政年份:2019
- 资助金额:
$ 31万 - 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
- 批准号:
398018062 - 财政年份:2018
- 资助金额:
$ 31万 - 项目类别:
Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9308643 - 财政年份:2017
- 资助金额:
$ 31万 - 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9447149 - 财政年份:2017
- 资助金额:
$ 31万 - 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
- 批准号:
8893915 - 财政年份:2014
- 资助金额:
$ 31万 - 项目类别: